Verrica Pharmaceuticals Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging -1.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.54 | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | $-0.60 | $-0.45 | +25.0% | Beat | |
| Q4 FY25 | $-0.44 | $-0.56 | -27.3% | Miss |
Back to VRCA overview · VRCA holders · VRCA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.